GENMAB A/S/S (OTCMKTS:GMXAY – Get Free Report) shares crossed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $25.42 and traded as low as $22.73. GENMAB A/S/S shares last traded at $23.12, with a volume of 2,491,240 shares traded.
GENMAB A/S/S Price Performance
The business has a fifty day simple moving average of $25.42 and a 200-day simple moving average of $26.91.
About GENMAB A/S/S
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).
Featured Articles
- Five stocks we like better than GENMAB A/S/S
- How to Invest in the Best Canadian Stocks
- Texas Roadhouse Stock Steering for New Highs This Year
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- How to Most Effectively Use the MarketBeat Earnings Screener
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for GENMAB A/S/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENMAB A/S/S and related companies with MarketBeat.com's FREE daily email newsletter.
